<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389437</url>
  </required_header>
  <id_info>
    <org_study_id>AMR_2020_3</org_study_id>
    <nct_id>NCT04389437</nct_id>
  </id_info>
  <brief_title>OCT-Angiography and Adaptive Optics in Patients With Memory Impairment</brief_title>
  <acronym>OCTAVO</acronym>
  <official_title>OCT-Angiography and Adaptive Optics in Patients With Memory Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive
      Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI :
      amnestic mild cognitive impairment), or to other neurodegenerative diseases such as
      frontotemporal dementia or Lewy body diseases.

      These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and
      adaptive optics (AO) appear different depending on the pathologies and could therefore serve
      as markers in vivo of the pathophysiological processes underlying NCD.

      No study to date has studied the retina and its vessels in NCD using adaptive optics. In this
      pilot study, we are proposing a combination of two new ophthalmological imaging techniques
      (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the
      morphology of small vessels as well as architecture of the retina to better specify the
      retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between
      patients with NCD and controls without NCD (with memory complaint or without) and will seek
      to determine if there are different profiles according to the causes of NCD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wall to lumen ratio (WLR)</measure>
    <time_frame>Baseline (Inclusion)</time_frame>
    <description>Measured in adaptive optics, compared between patients case with NCD and patient controls without NDC found</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Amnesia</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Lewy Body Disease</condition>
  <condition>Parkinsons Disease With Dementia</condition>
  <arm_group>
    <arm_group_label>NCD patients (case)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients with memory complaint</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal neuropsychological evaluation during assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients without memory complaint</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmological exam</intervention_name>
    <description>OCT-A and AO</description>
    <arm_group_label>Control patients with memory complaint</arm_group_label>
    <arm_group_label>Control patients without memory complaint</arm_group_label>
    <arm_group_label>NCD patients (case)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient presenting in memory consultation for memory complaint or person accompanying
             a patient in memory consultation for memory complaint

        Exclusion Criteria:

          -  pregnant or lactating women

          -  history of known non-degenerative neurological pathology (tumor, stroke territorial,
             in particular multiple sclerosis)

          -  history of retinal pathology

          -  ametropia greater in absolute value than 3 diopters on the sphere, and 1.5 diopters on
             the cylinder.

          -  history of taking ethambutol or synthetic antimalarial

          -  Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) &lt;10 for
             patients and 26 for accompanying persons

          -  MRI contraindication (for patients only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine MOULIGNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie YACHITZ, MD</last_name>
    <phone>(0)148036454</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antoine MOULIGNIER, MD</last_name>
    <email>amoulignier@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Fondation A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine MOULIGNIER, MP</last_name>
      <email>amoulignier@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Martine MAUGET FAYSSE, MD</last_name>
      <phone>(0)148036437</phone>
      <phone_ext>+33</phone_ext>
      <email>mmfaysse@for.paris</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT-A</keyword>
  <keyword>adaptative optics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Amnesia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

